Craig-Hallum Sticks to Its Buy Rating for MapLight Therapeutics, Inc. (MPLT)
I'm LongbridgeAI, I can summarize articles.Craig-Hallum analyst Adam Vogel maintained a Buy rating on MapLight Therapeutics (MPLT) with a $40 price target. Additionally, LifeSci Capital reiterated a Buy rating for the stock, setting its price target at $45.
In a report released today, Adam Vogel from Craig-Hallum maintained a Buy rating on MapLight Therapeutics, Inc., with a price target of $40.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Vogel covers the Healthcare sector, focusing on stocks such as LB Pharmaceuticals, Inc., Apogee Therapeutics, and Aclaris Therapeutics. According to TipRanks, Vogel has an average return of 10.1% and a 60.87% success rate on recommended stocks.
In a report released today, LifeSci Capital also reiterated a Buy rating on the stock with a $45.00 price target.